Y-Biologics, Inc. (KOSDAQ:338840)
South Korea
· Delayed Price · Currency is KRW
23,150
-550 (-2.32%)
At close: Apr 28, 2026
Y-Biologics Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 351,373 | 347,578 | 113,678 | 230,299 | - | - | |
| Market Cap Growth | 307.71% | 205.76% | -50.64% | - | - | - | |
| Enterprise Value | 321,857 | 324,452 | 102,035 | 230,749 | - | - | |
| Last Close Price | 23150.00 | 22900.00 | 7690.00 | 15600.00 | - | - | |
| PS Ratio | 120.62 | 119.32 | 19.73 | 66.19 | - | - | |
| PB Ratio | 13.21 | 13.07 | 5.79 | 8.86 | - | - | |
| P/TBV Ratio | 13.48 | 13.33 | 6.27 | 9.94 | - | - | |
| EV/Sales Ratio | 110.49 | 111.38 | 17.71 | 66.33 | - | - | |
| Debt / Equity Ratio | 0.56 | 0.56 | 0.04 | 0.11 | 0.25 | 0.21 | |
| Net Debt / Equity Ratio | -1.11 | -1.11 | -0.58 | -0.69 | -0.40 | -0.39 | |
| Net Debt / EBITDA Ratio | 4.02 | 4.02 | 1.78 | 2.31 | 0.51 | 0.73 | |
| Net Debt / FCF Ratio | 4.30 | 4.30 | 1.63 | 2.31 | 0.72 | 0.66 | |
| Asset Turnover | 0.08 | 0.08 | 0.22 | 0.12 | 0.12 | 0.11 | |
| Quick Ratio | 35.93 | 35.93 | 10.58 | 7.39 | 1.60 | 2.91 | |
| Current Ratio | 36.16 | 36.16 | 10.73 | 7.48 | 1.70 | 3.20 | |
| Return on Equity (ROE) | -181.79% | -181.79% | -28.23% | -90.84% | -77.73% | -54.50% | |
| Return on Assets (ROA) | -14.95% | -14.95% | -20.30% | -21.27% | -34.84% | -24.67% | |
| Return on Capital Employed (ROCE) | -17.00% | -17.00% | -41.10% | -37.00% | -90.60% | -54.20% | |
| Earnings Yield | -11.96% | -12.09% | -5.67% | -9.06% | - | - | |
| FCF Yield | -1.95% | -1.98% | -6.16% | -3.39% | - | - | |
| Buyback Yield / Dilution | -0.79% | -0.79% | -18.02% | -1.85% | -1.01% | -21.93% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.